Our Pricing

Is Mounjaro Safe? Clinical Evidence & UK Safety Profile

Published on: June 03, 2026

Is Mounjaro safe for weight loss and type 2 diabetes management? Mounjaro (tirzepatide) has demonstrated a robust safety profile across extensive clinical trials involving over 10,000 participants, with regulatory approval from the MHRA and FDA based on comprehensive safety data. While generally well-tolerated, understanding the evidence-based safety profile, potential side effects, and contraindications is essential before starting treatment.

Is Mounjaro Safe According to Clinical Trial Data?

Is Mounjaro safe based on rigorous clinical evidence? The SURPASS clinical trial programme evaluated tirzepatide safety across five major phase 3 trials involving 10,370 participants with type 2 diabetes, with treatment durations extending up to 104 weeks [1]. The overall safety profile showed that Mounjaro was generally well-tolerated, with most adverse events being mild to moderate in severity and transient in nature.

In the SURMOUNT weight management trials, which enrolled participants without diabetes, tirzepatide demonstrated consistent safety outcomes with the diabetes studies [2]. The most common adverse events were gastrointestinal, including nausea (reported in 20-40% of participants depending on dose), diarrhoea, and vomiting, typically occurring during dose escalation and diminishing over time. Serious adverse events were rare and occurred at similar rates to placebo in most studies.

Long-term safety data from the SURPASS-4 cardiovascular outcomes study followed participants for up to 3 years, providing reassurance about sustained tolerability [3]. Discontinuation rates due to adverse events ranged from 4-7% across doses, comparable to other GLP-1 receptor agonists used in clinical practice throughout the UK.

Is Mounjaro Safe Compared to Other Weight Loss Medications?

Is Mounjaro safe relative to alternative weight management treatments available in the UK? When compared directly to semaglutide 1mg in the SURPASS-2 trial, tirzepatide showed a similar overall safety profile, with gastrointestinal side effects being the primary tolerability concern for both medications [4]. The incidence of nausea was slightly higher with higher tirzepatide doses but generally resolved within 4-8 weeks of dose stabilisation.

Compared to older weight loss medications like orlistat, Mounjaro offers a different safety profile—orlistat primarily causes gastrointestinal effects related to fat malabsorption, while tirzepatide's effects are related to delayed gastric emptying and central appetite regulation. Neither medication has shown significant cardiovascular safety concerns; in fact, GLP-1 receptor agonists including tirzepatide have demonstrated cardiovascular benefits in clinical trials.

The UK's MHRA conducted comprehensive safety reviews before licensing Mounjaro for both type 2 diabetes and weight management, evaluating data from over 15,000 patient-years of exposure. This regulatory scrutiny provides additional assurance that is Mounjaro safe when prescribed appropriately by qualified healthcare professionals.

Head-to-Head Safety Comparison

Direct comparison studies show that tirzepatide's dual GIP/GLP-1 receptor agonism does not increase safety risks compared to GLP-1-only medications. The SURPASS-2 trial demonstrated that discontinuation rates due to adverse events were 6.2% for tirzepatide 10mg and 6.7% for tirzepatide 15mg, compared to 3.0% for semaglutide 1mg—a modest difference primarily driven by dose-dependent gastrointestinal effects [4].

Is Mounjaro Safe for Long-Term Use?

Is Mounjaro safe when used continuously over extended periods? Long-term safety data from the SURPASS-3 extension study, which followed participants for up to 2 years, showed no emergence of new safety signals with prolonged tirzepatide exposure [5]. Adverse event rates actually decreased over time as participants adapted to treatment, with gastrointestinal side effects becoming less frequent after the initial 20-24 weeks.

Chronic medication safety concerns such as pancreatitis, gallbladder disease, and thyroid effects have been carefully monitored across all tirzepatide trials. Acute pancreatitis occurred in less than 0.2% of participants, rates similar to background population risk. Cholelithiasis (gallstones) occurred more frequently with tirzepatide than placebo, likely related to rapid weight loss rather than direct medication effects—a pattern observed with all effective weight loss interventions.

The MHRA and European Medicines Agency continue to monitor post-marketing safety data as Mounjaro use expands across the UK. Current evidence supports long-term safety when treatment is supervised by healthcare professionals and patients are monitored appropriately for potential complications. At Cured Pharmacy, all Mounjaro prescriptions are assessed by UK-registered prescribers who evaluate individual suitability and ongoing safety.

Monitoring Requirements for Safe Long-Term Use

To ensure Mounjaro remains safe during extended treatment, UK prescribers typically recommend monitoring HbA1c or weight every 3-6 months, along with assessment for gastrointestinal symptoms, signs of pancreatitis, and gallbladder disease. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use tirzepatide due to theoretical thyroid C-cell tumour risk observed in rodent studies.

Is Mounjaro Safe During Pregnancy and for Specific Populations?

Is Mounjaro safe for women of childbearing potential and other special populations? Tirzepatide is contraindicated during pregnancy and should be discontinued at least 2 months before a planned pregnancy due to the long half-life of the medication [6]. Animal studies showed potential foetal harm, and there are no adequate human pregnancy data to establish safety. Women of childbearing potential should use effective contraception while taking Mounjaro.

For older adults, clinical trials included participants up to age 75, and no overall differences in safety were observed compared to younger adults, though gastrointestinal side effects may be less well-tolerated in frail elderly patients. Renal impairment does not require dose adjustment, as tirzepatide is primarily eliminated via protein catabolism rather than renal excretion, making it safer than some alternatives in patients with kidney disease.

Mounjaro has not been studied in patients under 18 years of age and is not recommended for paediatric use in the UK. Individuals with a history of severe gastrointestinal disease, including gastroparesis or inflammatory bowel disease, should discuss potential risks with their prescriber, as delayed gastric emptying could theoretically worsen these conditions.

Is Mounjaro Safe: Understanding Common Side Effects

Is Mounjaro safe given its side effect profile? Understanding what to expect helps patients distinguish between normal, transient effects and concerning symptoms requiring medical attention. The most common side effects are gastrointestinal: nausea affects 20-40% of users (dose-dependent), diarrhoea 15-25%, vomiting 8-18%, and constipation 10-15% [1]. These effects typically peak during the first 4-8 weeks of each new dose and diminish substantially as the body adapts.

Less common but notable side effects include injection site reactions (redness, itching), fatigue, and decreased appetite—the latter being a therapeutic effect contributing to weight loss. Hypoglycaemia is rare when Mounjaro is used alone but increases when combined with insulin or sulphonylureas, requiring dose adjustments of these concurrent medications by a prescriber.

Serious adverse events are uncommon but include acute pancreatitis (sudden severe abdominal pain), acute gallbladder disease (right upper quadrant pain, especially after meals), and severe allergic reactions. The UK's Yellow Card scheme encourages reporting of suspected side effects to the MHRA, contributing to ongoing safety surveillance. At £124.99, Mounjaro from Cured Pharmacy includes access to UK-registered clinical support for managing any side effects that arise during treatment.

Managing Side Effects Safely

To optimise safety and tolerability, prescribers recommend starting at the lowest dose (2.5mg weekly) and gradually escalating every 4 weeks. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce gastrointestinal side effects. If nausea persists beyond the first month at a stable dose, anti-emetic medications or temporary dose reduction may be appropriate under prescriber guidance.

Is Mounjaro Safe: Contraindications and Drug Interactions

Is Mounjaro safe for everyone, or are there absolute contraindications? Mounjaro should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2), due to thyroid C-cell tumour risk observed in animal studies [6]. While no cases of MTC have been confirmed as caused by tirzepatide in humans, this remains a precautionary contraindication enforced by UK prescribers.

Type 1 diabetes is another contraindication—Mounjaro is not a substitute for insulin and should not be used in patients with absolute insulin deficiency. History of severe hypersensitivity to tirzepatide or any excipients is also a contraindication. Patients with diabetic ketoacidosis should not initiate Mounjaro until the acute condition is resolved.

Drug interactions are relatively limited but clinically important. Mounjaro delays gastric emptying, which can affect absorption of oral medications, particularly those requiring rapid absorption or narrow therapeutic windows. Warfarin and other oral anticoagulants may require more frequent INR monitoring when starting tirzepatide. Oral contraceptives should be taken at least 1 hour before or 4 hours after Mounjaro injection during the first 4 weeks of treatment or after dose escalation to ensure adequate absorption. UK prescribers at Cured Pharmacy review all concurrent medications during assessment to identify potential interactions and ensure Mounjaro is safe for each individual patient.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 13 August 2026]
3. Del Prato, S., Kahn, S. E., Pavo, I., et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10313), 1811-1824. [accessed 13 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10295), 157-169. [accessed 13 August 2026]
5. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583-598. [accessed 13 August 2026]
6. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Medicines and Healthcare products Regulatory Agency. [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.